Hutchmed (China) (HKG:0013) completed the enrollment of patients with intrahepatic cholangiocarcinoma, or bile duct cancer, for the phase ІІ trial of its fanregratinib medication, a Thursday filing with the Hong Kong bourse said.
A total of 87 patients were enrolled in the study.
The first patient received the first dose in March 2023, with the pharmaceutical company expected to announce topline results from the study around the end of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.